DK1140889T3 - Forbindelser og metoder til modulation af estrogen-receptorer - Google Patents

Forbindelser og metoder til modulation af estrogen-receptorer

Info

Publication number: DK1140889T3
Authority: DK; Denmark
Prior art keywords: methods; disclosed; compounds; same; modulation
Prior art date: 1998-12-30

Application number

DK99968578T

Other languages

Danish (da)

English (en)

Inventor

Bernd M Stein

David W Anderson

Leah M Gayo

May S Sutherland

Mary Doubleday

Graziella I Shevlin

Adam Kois

Sak Khammungkhune

Ravi Kumar Jalluri

Shripad S Bhagwat

Jeffrey A Mckie

Original Assignee

Signal Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-30

Filing date

1999-12-30

Publication date

2003-12-22

1999-12-30 Application filed by Signal Pharm Inc filed Critical Signal Pharm Inc

2003-12-22 Application granted granted Critical

2003-12-22 Publication of DK1140889T3 publication Critical patent/DK1140889T3/da

Links

102000015694 estrogen receptors Human genes 0.000 title abstract 4
108010038795 estrogen receptors Proteins 0.000 title abstract 4
150000001875 compounds Chemical class 0.000 title abstract 2
208000000044 Amnesia Diseases 0.000 abstract 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
201000009273 Endometriosis Diseases 0.000 abstract 1
208000033830 Hot Flashes Diseases 0.000 abstract 1
206010060800 Hot flush Diseases 0.000 abstract 1
208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
208000026139 Memory disease Diseases 0.000 abstract 1
206010027951 Mood swings Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
230000002411 adverse Effects 0.000 abstract 1
210000000988 bone and bone Anatomy 0.000 abstract 1
210000000481 breast Anatomy 0.000 abstract 1
210000000748 cardiovascular system Anatomy 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
230000002500 effect on skin Effects 0.000 abstract 1
239000003256 environmental substance Substances 0.000 abstract 1
229940011871 estrogen Drugs 0.000 abstract 1
239000000262 estrogen Substances 0.000 abstract 1
230000014509 gene expression Effects 0.000 abstract 1
230000003054 hormonal effect Effects 0.000 abstract 1
230000006984 memory degeneration Effects 0.000 abstract 1
208000023060 memory loss Diseases 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
210000002307 prostate Anatomy 0.000 abstract 1
201000004240 prostatic hypertrophy Diseases 0.000 abstract 1
230000001850 reproductive effect Effects 0.000 abstract 1
210000001519 tissue Anatomy 0.000 abstract 1
210000004291 uterus Anatomy 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Neurology (AREA)
Obesity (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Child & Adolescent Psychology (AREA)
Immunology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrane Compounds (AREA)

DK99968578T 1998-12-30 1999-12-30 Forbindelser og metoder til modulation af estrogen-receptorer DK1140889T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11447298P	1998-12-30	1998-12-30
PCT/US1999/031290 WO2000039120A2 (en)	1998-12-30	1999-12-30	Compounds and methods for modulation of estrogen receptors

Publications (1)

Publication Number	Publication Date
DK1140889T3 true DK1140889T3 (da)	2003-12-22

Family

ID=22355427

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99968578T DK1140889T3 (da)	1998-12-30	1999-12-30	Forbindelser og metoder til modulation af estrogen-receptorer

Country Status (14)

Country	Link
EP (1)	EP1140889B1 (de)
JP (1)	JP2002533456A (de)
KR (1)	KR100615757B1 (de)
CN (2)	CN100339374C (de)
AT (1)	ATE248157T1 (de)
AU (1)	AU765159B2 (de)
CA (1)	CA2356986A1 (de)
DE (1)	DE69910830T2 (de)
DK (1)	DK1140889T3 (de)
ES (1)	ES2207982T3 (de)
HK (1)	HK1041258B (de)
IL (2)	IL144003A0 (de)
PT (1)	PT1140889E (de)
WO (1)	WO2000039120A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6822563B2 (en)	1997-09-22	2004-11-23	Donnelly Corporation	Vehicle imaging system with accessory control
US5877897A (en)	1993-02-26	1999-03-02	Donnelly Corporation	Automatic rearview mirror, vehicle lighting control and vehicle interior monitoring system using a photosensor array
US7655894B2 (en)	1996-03-25	2010-02-02	Donnelly Corporation	Vehicular image sensing system
US6331562B1 (en)	1998-12-30	2001-12-18	Signal Pharmaceuticals, Inc.	Compounds and methods for modulation of estrogen receptors
US6291456B1 (en)	1998-12-30	2001-09-18	Signal Pharmaceuticals, Inc.	Compounds and methods for modulation of estrogen receptors
CA2367895A1 (en)	1999-03-17	2000-09-21	Signal Pharmaceuticals, Inc.	Compounds and methods for modulation of estrogen receptors
US6593322B1 (en)	1999-03-17	2003-07-15	Signal Pharmaceuticals, Inc.	Compounds and methods for modulation of estrogen receptors
ATE289300T1 (de) *	1999-12-30	2005-03-15	Signal Pharm Inc	Verbindungen und verfahren zur modulation von estrogen rezeptoren
EP1177787A3 (de) *	2000-07-28	2003-09-10	Pfizer Products Inc.	Verwendung von einem Östrogen Agonist/Antagonist zur Behandlung von Katarakt
IL157065A0 (en) *	2001-01-24	2004-02-08	Chiesi Farma Spa	2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
EP1281710A1 (de) *	2001-08-03	2003-02-05	CHIESI FARMACEUTICI S.p.A.	2H-1-Benzopyran derivat, Verfahren zur Herstellung und diese enthaltende pharmazeutische Zusammenstellungen
ES2236056T3 (es) *	2001-01-24	2005-07-16	Chiesi Farmaceutici S.P.A.	Derivados de 2h-1-benzopirano, procedimientos para su preparacion y composiciones farmaceuticas de los mismos.
EP1386919A4 (de) *	2001-04-10	2010-03-10	Takara Bio Inc	Heilmittel
US7148252B2 (en) *	2001-10-03	2006-12-12	Signal Pharmaceuticals, Llc	Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis
UA83620C2 (ru)	2001-12-05	2008-08-11	Уайт	Замещенные бензоксазолы и их аналоги как эстрогенные агенты
EP1497277A1 (de) *	2002-04-19	2005-01-19	Signal Pharmaceuticals, Inc.	Benzopyranon-verbindungen, diese enthaltende zusammensetzungen und methoden zur behandlung damit
AU2003225228A1 (en)	2002-05-03	2003-11-17	Donnelly Corporation	Object detection system for vehicle
US7091235B2 (en)	2002-10-15	2006-08-15	Signal Pharmaceuticals, Llc	Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer
FR2849653B1 (fr) *	2003-01-08	2006-08-25	B F B Etudes Et Rech S Experim	Derives de la coumarine ayant une affinite pour les recepteurs aux estrogenes, procede pour leur preparation et compositions pharmaceutiques en contenant
AU2004274445A1 (en)	2003-09-15	2005-03-31	Novartis Ag	Benzopyranone compounds, compositions thereof, and methods of treatment therewith
US7526103B2 (en)	2004-04-15	2009-04-28	Donnelly Corporation	Imaging system for vehicle
AU2006206446A1 (en) *	2005-01-21	2006-07-27	Janssen Pharmaceutica N.V.	Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
WO2007002272A1 (en) *	2005-06-24	2007-01-04	Signal Pharmaceuticals, Llc	Benzopyranone compounds for treating cancer
AR059339A1 (es)	2006-02-09	2008-03-26	Chugai Pharmaceutical Co Ltd	Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
EP1860104A1 (de) *	2006-05-22	2007-11-28	Aptanomics	Von 3-Arylcoumarin oder 3-Arylchinolin-2-on abgeleitete antiproliferative Verbindungen und ihre Verwendung
CN101200460B (zh) *	2007-11-19	2010-06-16	北京珅奥基医药科技有限公司	二氢苯并吡喃酮类化合物及其用途
CN105541810B (zh) *	2016-03-04	2019-05-17	南京工业大学	一种香豆素类nedd8激活酶抑制剂及其制备方法与应用
CN105801543B (zh) *	2016-04-18	2019-08-02	中国药科大学	4-芳香胺-香豆素衍生物及其制备方法和医药用途
CN105801544A (zh) *	2016-04-18	2016-07-27	中国药科大学	3-芳基-4-芳香胺-香豆素衍生物及其制备方法和医药用途
CN112426420B (zh) *	2020-12-01	2021-12-28	浙江大学	香豆素-二硫代氨基甲酸酯衍生物在制备抗肿瘤药物中的应用
CN112645922B (zh) *	2020-12-24	2022-01-07	中国人民解放军空军军医大学	香豆素类化合物、制备方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2857401A (en) *	1956-12-20	1958-10-21	Searle & Co	Acetylated coumarin derivatives
DE4323409A1 (de) *	1993-07-13	1995-01-19	Boehringer Mannheim Gmbh	Verwendung von Cumarinen und Carbostyrilen als PLA¶2¶-Inhibitoren, neue Cumarine und Carbostyrile, Verfahren zu ihrer Herstellung und Arzneimittel
JPH10513470A (ja) *	1995-02-06	1998-12-22	イーライ・リリー・アンド・カンパニー	Ｉｌ−６の効果を阻害する方法
EP0937058A1 (de) *	1996-10-28	1999-08-25	Novo Nordisk A/S	$i(CIS)-3,4-CHROMANDERIVATE ZUR VORBEUGUNG ODER BEHANDLUNGVON OESTROGENBEZOGENEN KRANKHEITEN ODER SYNDROMEN
EP0937059A1 (de) *	1996-10-28	1999-08-25	Novo Nordisk A/S	$i(TRANS)-3,4-CHROMANDERIVATE ZUR VORBEUGUNG ODER BEHANDLUNGVON OESTROGENBEZOGENEN KRANKHEITEN ODER SYNDROMEN
CA2270111A1 (en) *	1996-10-28	1998-05-07	Lise Brown Christiansen	Novel (-)-enantiomers of cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
JP2001502708A (ja) *	1996-10-28	2001-02-27	ノボノルディスクアクティーゼルスカブ	エストロゲン関連の疾患または症候群の予防または治療に有用な新規なシス―３，４―クロマン誘導体
ES2188909T3 (es) *	1996-10-28	2003-07-01	Novo Nordisk As	Nuevos derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes o enfermedades relacionados con el estrogeno. os
ZA979644B (en) *	1996-10-28	1998-04-28	Novo Nordisk As	Heterocyclic compounds, compositions and uses.

1999
- 1999-12-30 JP JP2000591031A patent/JP2002533456A/ja active Pending
- 1999-12-30 HK HK02101413.5A patent/HK1041258B/en not_active IP Right Cessation
- 1999-12-30 WO PCT/US1999/031290 patent/WO2000039120A2/en not_active Ceased
- 1999-12-30 EP EP99968578A patent/EP1140889B1/de not_active Expired - Lifetime
- 1999-12-30 AU AU25970/00A patent/AU765159B2/en not_active Ceased
- 1999-12-30 AT AT99968578T patent/ATE248157T1/de not_active IP Right Cessation
- 1999-12-30 ES ES99968578T patent/ES2207982T3/es not_active Expired - Lifetime
- 1999-12-30 CA CA002356986A patent/CA2356986A1/en not_active Abandoned
- 1999-12-30 KR KR1020017008410A patent/KR100615757B1/ko not_active Expired - Fee Related
- 1999-12-30 IL IL14400399A patent/IL144003A0/xx active IP Right Grant
- 1999-12-30 DE DE69910830T patent/DE69910830T2/de not_active Expired - Fee Related
- 1999-12-30 CN CNB2004100422993A patent/CN100339374C/zh not_active Expired - Fee Related
- 1999-12-30 CN CNB998163740A patent/CN1155589C/zh not_active Expired - Fee Related
- 1999-12-30 DK DK99968578T patent/DK1140889T3/da active
- 1999-12-30 PT PT99968578T patent/PT1140889E/pt unknown
2001
- 2001-06-26 IL IL144003A patent/IL144003A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU765159B2 (en)	2003-09-11
IL144003A0 (en)	2002-04-21
ES2207982T3 (es)	2004-06-01
ATE248157T1 (de)	2003-09-15
WO2000039120A2 (en)	2000-07-06
DE69910830D1 (de)	2003-10-02
HK1075893A1 (zh)	2005-12-30
AU2597000A (en)	2000-07-31
JP2002533456A (ja)	2002-10-08
CA2356986A1 (en)	2000-07-06
KR20010101346A (ko)	2001-11-14
PT1140889E (pt)	2004-01-30
EP1140889A2 (de)	2001-10-10
DE69910830T2 (de)	2004-06-17
HK1041258A1 (en)	2002-07-05
WO2000039120A3 (en)	2000-10-26
EP1140889B1 (de)	2003-08-27
CN1155589C (zh)	2004-06-30
CN100339374C (zh)	2007-09-26
CN1337958A (zh)	2002-02-27
HK1041258B (en)	2003-12-12
IL144003A (en)	2006-07-05
KR100615757B1 (ko)	2006-08-25
CN1597677A (zh)	2005-03-23

Publication	Publication Date	Title
PT1140889E (pt)	2004-01-30	Compostos e metodos para modulacao de receptores de estrogenio
DK1246814T3 (da)	2005-05-30	Forbindelser og fremgangsmåder til modulation af östrogenreceptorer
WO2000055137A8 (en)	2001-07-05	Compounds and methods for modulation of estrogen receptors
ATE355279T1 (de)	2006-03-15	Pyrazole als modulatoren des östrogenrezeptors
Lemmen et al.	1999	Expression of estrogen receptor alpha and beta during mouse embryogenesis
YU596A (sh)	1998-12-23	Estrogen agonisti/antagonisti
DE69838177D1 (de)	2007-09-13	Androgensyntheseinhibitoren
MX9505249A (es)	1997-01-31	Agonistas de estrogeno.
DK0946189T3 (da)	2002-12-16	Anvendelse af aktivatorer af CNTF (ciliær neurotrofisk faktor) receptor til behandling af adipositas
ATE183516T1 (de)	1999-09-15	Waisen-rezeptor
ATE292468T1 (de)	2005-04-15	Verwendung von biogenen estrogensulfamaten zur hormonsubstitutionstherapie
Nenci et al.	1988	Commentary on human mammary preneoplasia. The estrogen receptor-promotion hypothesis
NZ515353A (en)	2004-03-26	Cyclothiocarbamate derivatives as progesterone receptor modulators
NO984631D0 (no)	1998-10-02	<alfa>1-Adrenerge reseptor-antagonister
NO983724D0 (no)	1998-08-13	17-<beta>-syklopropyl (amino/oksi)-4-aza-steroider som aktive inhibitorer av testosteron-5-<alfa>-reduktase og C17-20-lylase
Friedman	2005	The Estradiol-Dihydrotestosterone model of prostate cancer
Zierau et al.	2004	Two major metabolites of 8-prenylnaringenin are estrogenic in vitro
DK0898708T3 (da)	2002-03-04	Interaktion af cyclin D1 og estrogenreceptor og anvendelse deraf i assays
DK1196428T3 (da)	2005-01-24	11-beta-aryl-17,17-spirothiolan-substituerede steroider
MY137604A (en)	2009-02-27	Benzopyranone compounds, compositions thereof, and methods of treatment therewith
ATE236924T1 (de)	2003-04-15	8-substituierte b-nor-6-thiaequilin verbindungen als selektiven östrogenrezeptormodulatoren
Meyers	1984	The role of hormone receptors in estrogen activity is questionable
Charnock-Jones et al.	1998	Vascular endothelial growth factor and corpus luteum angiogenesis
Boyde	1984	Stereographic visual aids
Carmel et al.	2009	ROLE OF ANGIOTENSIN II RECEPTORS IN PROSTATE CANCER: 1330